Glycoengineering & Glycoform Optimization Services

At Elise Biopharma, we recognize that the sugar chains attached to your therapeutic proteins—known as glycans—are far more than decorations. They govern half-life, efficacy, immunogenicity, and even safety. Our Glycoengineering & Glycoform Optimization services transform host cells into precision machines, sculpting glycan profiles to your exact specifications. Whether you’re developing next-generation antibodies, enzyme replacements, or Fc-fusion decoys, our integrated glycosylation engineering platform ensures optimal glycoform distributions, consistent batch-to-batch quality, and a fast track to clinical success.

Why Glycoengineering Matters
  1. Extend Serum Half-Life
    • Sialylation and terminal galactose residues engage with hepatic lectin receptors to delay clearance.
    • Optimized Fc glycoforms exploit FcRn recycling for multi-week dosing intervals.
  2. Tune Effector Functions
    • Afucosylation enhances ADCC by increasing affinity to FcγRIIIa on NK cells.
    • Controlled bisecting N-acetylglucosamine (GlcNAc) modulates CDC and ADCP.
  3. Reduce Immunogenicity
    • Human-like glycan patterns minimize anti-drug antibody (ADA) responses.
    • Eliminate non-human structures (α-Gal, Neu5Gc) that trigger hypersensitivity.
  4. Improve Stability & Solubility
    • Certain glycoforms shield hydrophobic patches, reducing aggregation.
    • Glycan–protein interactions can stabilize tertiary structure under stress.
Our Glycoengineering CDMO Platform

Elise Biopharma’s proprietary platform integrates molecular design, cell line engineering, process development, and advanced analytics into a seamless glycoform optimization workflow:

ModuleCapabilities
Host Cell EngineeringCHO, HEK293, Pichia pastoris with targeted knock-ins/knock-outs (GNTI, FUT8, ST3GAL, B4GALT)
Vector & ExpressionGlyco-optimized expression cassettes, signal peptide tuning, promoter selection for balanced expression
Upstream Process DesignMedia supplementation with Mn²⁺, uridine; feed strategy for glycan precursors; temperature and pH modulation
Downstream PurificationLectin affinity chromatography, mixed-mode resins for glycoform fractionation, size-exclusion polishing
Analytical CharacterizationLC-MS/MS glycopeptide mapping, HILIC-FLD glycan profiling, CE-SDS for charge variants
Regulatory SupportCMC documentation for glycan critical quality attributes (CQAs), comparability protocols, IND/BLA filing support

Host Cell Engineering & Strain Selection

3.1 Choosing the Right Host

  • CHO Cells
    • Gold standard for human-like N-glycans; robust growth and regulatory familiarity.
  • HEK293 Cells
    • Superior sialylation machinery; valuable for highly sialylated glycoforms.
  • P. pastoris (Glycoengineered Strains)
    • Rapid growth and simple media; custom strains programmed for human-type glycosylation.

3.2 Genetic Modifications

  • Knock-Outs
    • GNTI-KO: Produces high-mannose glycoforms for rapid clearance models or specific enzyme products.
    • FUT8-KO: Eliminates core fucose for enhanced ADCC.
  • Knock-Ins
    • ST3GAL1/4, B4GALT1/2: Increase terminal sialylation and galactosylation.
    • Human α-2,6-sialyltransferase to achieve human-specific sialic acid linkages.

3.3 Single-Cell Cloning & Screening

Using FACS and automated imaging, we isolate monoclonal cell lines with optimal growth, productivity, and glycoform consistency. Stability studies confirm > 90% desired glycoform retention over 60+ population doublings.

Upstream Process Development for Glycoform Control

4.1 Media Design & Feed Strategies

  • Media Supplements:
    • Manganese (Mn²⁺): Cofactor for galactosyltransferases.
    • Uridine & Galactose: Precursor sugars for glycan extension.
  • Feed Timing & Composition:
    • Bolus vs. continuous feed to maintain steady‐state sugar levels.
    • Custom feed blends to balance growth vs. glycosylation pathways.

4.2 Bioreactor Parameter Optimization

  • pH Shifts:
    • Slight alkaline shift (pH 7.2–7.4) favors galactosylation.
  • Temperature Reduction:
    • Lowering from 37 °C to 30–32 °C post-induction extends glycosyltransferase half-life.
  • Dissolved Oxygen (DO):
    • High DO (> 40% saturation) ensures energy for glycan biosynthesis.

4.3 High-Throughput DoE Screening

Using micro-bioreactors (AMBR®), we run factorial designs to pinpoint critical process parameters (CPPs) that drive glycoform distributions. Typical screening matrix:

VariableLevels
Temperature (°C)30, 32, 34
pH Setpoint7.0, 7.2, 7.4
Mn²⁺ (µM)10, 20, 40
Feed Rate (mL/L/h)0.5, 1.0, 1.5

Downstream Purification & Glycoform Fractionation

5.1 Lectin Affinity Chromatography

  • Concanavalin A (ConA): Captures high-mannose and hybrid glycans.
  • Aleuria aurantia lectin (AAL): Binds fucosylated glycoforms for targeted removal.

5.2 Mixed-Mode & IEX Polishing

  • Mixed-Mode Resins: Combine ionic and hydrophobic interactions to resolve closely related glycoforms.
  • Cation/Anion Exchange: Separate charge variants arising from sialylation differences.

5.3 Size-Exclusion & HIC

  • SEC: Final polishing to remove high-molecular-weight aggregates that can co-elute with certain glycoforms.
  • HIC: Exploit subtle hydrophobicity changes introduced by glycan modifications.

Analytical Characterization & Quality Control

AssayPurpose
LC-MS/MS Glycopeptide MappingSite-specific glycan composition
HILIC-FLD Glycan ProfilingQuantitative glycan distribution (2AA labeling)
CE-SDS Charge Variant AnalysisDetects sialylation and deamidation variants
1D/2D-SDS-PAGE & Western BlotAssess molecular weight shifts
SPR/BLI FcRn BindingFunctional half-life correlate
Cell-Based Fc Effector AssaysADCC, CDC, and ADCP potency
Stability StudiesReal-time & accelerated glycoform integrity
Endotoxin & Host-Cell Protein (HCP)Ensure safety and purity

Each batch is benchmarked against pre-defined glycan critical quality attributes (CQAs) to guarantee consistency and regulatory compliance.

Regulatory & CMC Support

  • Glycan CQA Definition: Establish glycoform ranges critical for safety and efficacy.
  • Comparability Protocols: Demonstrate equivalence between R&D and GMP lots via head-to-head analytical studies.
  • IND/BLA Filings: Comprehensive CMC documentation, including glycosylation pathways, CPP tables, and analytical methods validation.
  • Global Compliance: Alignment with FDA, EMA, and ICH Q6B guidelines on glycan characterization.

Case Study: Afucosylated Antibody Enhancement

Challenge: A mid-stage oncology biotech needed an afucosylated monoclonal antibody to boost ADCC.
Solution Workflow:

  1. FUT8 Knock-Out in CHO-S host via CRISPR/Cas9.
  2. Screening & Cloning: 200 single clones evaluated; top line produced 4 g/L with < 5% fucosylation.
  3. Process Development: Optimized feed strategy with Mn²⁺ depletion post-peak to prevent residual fucosylation.
  4. Analytics: Achieved > 95% afucosylation confirmed by HILIC-FLD.
  5. GMP Manufacturing: Two 1,000 L runs delivered clinical-grade drug substance with consistent glycoform profiles.

Outcome: IND clearance in 8 months; first-in-human trial initiated on schedule.

Workflow: From Concept to Clinic

  1. Discovery & Feasibility (4–6 weeks)
    • In silico glycosylation modeling and target glycoform specification.
    • Small-scale expression screen and preliminary glycan analysis.
  2. Cell Line Generation (8–12 weeks)
    • Host engineering, vector design, transfection, and single-cell cloning.
    • Productivity and glycoform screening in multiwell plates.
  3. Process Definition (6–8 weeks)
    • Micro-bioreactor DoE for CPP identification.
    • Scale-up to bench-top bioreactors with optimized feed and control strategies.
  4. GMP Manufacturing (12–16 weeks)
    • Technology transfer, facility qualification, and GMP campaign scheduling.
    • Bulk drug substance production, downstream purification, and release testing.
  5. Regulatory Filing & Support (Concurrent)
    • CMC dossier preparation, glycan CQA justifications, and assay validations.
    • IND/BLA submission assistance and health authority interactions.
  6. Post-Launch Support
    • Continuous process verification (CPV), comparability for lifecycle management, and process improvements.

Glycoengineering CDMO FAQs

1) What’s the realistic timeline from feasibility to IND-enabling GMP for glycoengineering?

Most programs move 6–9 months end-to-end, but the levers are:

  • Feasibility (4–6 weeks): host/construct confirmation, micro-bioreactor DoE on pH/temperature/osmolality, rapid HILIC-FLD profile + LC-MS glycopeptide map; early FcRn/FcγRIIIa binding to connect glycan trends to function.
  • Cell-line & process definition (8–12 weeks): host pathway edits (e.g., FUT8, GNTI, ST3GAL, B4GALT), clone selection under perturbation (titer + glycan stability), upstream design space (capacitance-driven temp/pH shifts).
  • DSP/formulation (6–8 weeks): fractionation or polish tuned to glycoform windows; low-shear UF/DF; stress mapping to protect labile sialylation.
  • Engineering → GMP (8–12+ weeks): tech-transfer pack, PPQ plan, and analytics validation. Perfusion or continuous capture can shorten cycle time, but we only deploy when CQAs remain within limits across residence-time distributions.
2) Can you go beyond “standard Fc glycans” into hybrid, high-mannose, or designer architectures?

Yes—by design, not accident. We combine:

  • Host pathway engineering: FUT8-KO (afucosylation), GNTI-KO (high-mannose), ST3GAL/B4GALT knock-ins (terminal sialylation/galactose), and CMP-sialic acid flux tuning.
  • Media chemistries: Mn²⁺, uridine/galactose, nucleotide sugar precursors; osmolality shaping to bias Golgi residence time.
  • Process choreography: controlled temp/pH ramps to modulate glycosyltransferase activity; specific productivity (qP) tuning so quality doesn’t collapse at peak output.
  • Analytical steering: live HILIC sentinels during development guide set-points to hit hybrid or bespoke targets (e.g., bisected GlcNAc, α2,6-sialylation).
3) How do you ensure batch-to-batch consistency in glycoform distributions?

We make glycoform CV a controlled outcome via:

  • Soft-sensor PAT + MPC: Raman/FTIR for glucose/lactate/ammonia, capacitance for viable cell volume, off-gas OUR/CTR; model-predictive control holds pH/DO/temp/feed where glycan transfer is stable.
  • Clone selection under stress: rank by glycan integrity across pH/temp perturbations, not just titer.
  • Polish tuned to quality, not convenience: CEX windows narrow charge variants linked to off-target glycans; mixed-mode removes sticky outliers.
  • CPV with model residuals: we trend not only CQA charts but also soft-sensor residuals—early warning that precedes drift. Result: <5% glycoform variability after lock.
4) Are your glycoengineering processes fully cGMP-compliant?

Absolutely. We operate under FDA 21 CFR Part 211, EU GMP, and analytical expectations from ICH Q6B. You receive:

  • Method lifecycle docs (development → qualification/validation), assay version control, and ALCOA+ data integrity in the historian.
  • PPQ plans with challenge tests relevant to glyco CQAs (e.g., temp excursions), and a CPV scheme that includes periodic chemometric re-qualification.
  • Change control & comparability templates for clone/scale/site moves, with glycan-centric acceptance ranges and equivalence statistics.
5) What analytics do you run for glycan and quality characterization?

A full, orthogonal suite:

  • HILIC-FLD (2-AB/2-AA) for quantitative glycan distributions and sialylation/galactose trends.
  • LC-MS/MS glycopeptide mapping for site-specific occupancy and microheterogeneity.
  • icIEF/CEX-HPLC for charge variants tied to sialylation/deamidation.
  • SEC-MALS for aggregate/fragment, CE-SDS (r/nr) for integrity.
  • SPR/BLI for FcγRIIIa/FcRn binding; cell-based ADCC/CDC/ADCP potency models.
  • Release residuals: HCP (platform/custom), host-cell DNA, Protein A leachables.
6) How do you hit an afucosylation spec without sacrificing productivity?

We combine FUT8 attenuation (host or media levers) with DoE-mapped temp/pH schedules and feeding that stabilizes qP. We verify via HILIC and FcγRIIIa binding and lock with MPC so afucosylation stays on target as density and oxygen demand change.

7) Can you increase terminal sialylation for half-life extension?

Yes. We tune ST3GAL/β4GalT expression and nucleotide sugar supply, shape Golgi residence via temperature/osmolality profiles, and confirm with LC-MS glycopeptide readouts. FcRn binding + PK modeling translate the glycan shift into exposure predictions.

8) What if we need non-canonical or hybrid glycans for mechanism?

We can program bisected GlcNAc, high-mannose windows, or hybrid architectures by combining pathway edits with process levers, then separate residual off-targets with CEX/mixed-mode. Feasibility first de-risks biology; only then do we harden in GMP.

9) How do you prevent glycoform drift during scale-up or site transfer?

Keep the physics, adapt the “shell.” Our digital twin preserves transport/kinetic parameters and re-fits plant-specific quirks (sparger, probe lag) on anchor batches. Comparability is demonstrated on glycan CQAs with predefined acceptance ranges and documented controller equivalence.

10) Can you run perfusion while holding glycoforms steady?

Yes—with retention stability models, virus-safety overlays, and MPC-controlled temp/pH/DO. We monitor glycan sentinels in campaign to ensure residence-time distributions don’t push quality out of spec.

11) Do polishing steps change glycoform distributions?

They can. We design CEX/HIC windows to avoid biasing glyco spectra and validate with pre/post profiles. Where needed, we fractionate and recombine to meet both potency and glycan targets without yield penalties.

12) How do you map glyco CQAs to functional potency?

We correlate HILIC bins/site-specific LC-MS with ADCC/CDC/ADCP and FcRn data using MVDA. That mapping becomes your CPP→CQA→Clinical argument in the CMC narrative.

13) What’s your plan for process deviations that threaten glycan quality?

The twin flags risk (e.g., temp spike), MPC holds bounds, and we execute on-line corrections within validated ranges. Deviations capture cause/effect; CPV residuals decide whether preventive CAPA is needed.

14) Can you hit lot-specific glycoform “recipes” for regional filing strategies?

Yes—within validated design space. We propose recipe cards (temp/pH/feed micro-shifts, polish cut-points) and lock them with comparability and robustness data so regional specs can be met without new PPQ.

15) How do you quantify microheterogeneity at each glycosylation site?

LC-MS glycopeptide mapping with site-resolved spectra and relative abundance, cross-checked by released-glycan HILIC for quantitation. We trend site occupancy and distribution across development, engineering, and PPQ.

16) Do you support afucosylation for bispecifics and Fc-fusions?

Yes—pathway control is format-agnostic. We validate on each scaffold because folding/assembly kinetics can influence access to glycosyltransferases.

17) What upstream levers matter most for glycan control?

Temperature, pH, osmolality, and specific feed rate—governed by MPC using soft sensors. Secondary levers: ammonia and lactate trajectories (Raman-inferred), which alter glycan enzymes and need tight control.

18) Can you maintain glycan quality in high-density intensified fed-batch?

Yes. We densify seeds, apply gentler temp profiles, ensure oxygen/heat headroom, and protect glycan enzymes from pH transients. Intensification proceeds only after sentinel glycans remain stable over pilot runs.

19) How do you choose between site-directed cell engineering and media/process tweaks?

We run an impact × complexity decision: if a media/process lever delivers the target with robustness, we avoid genome edits; if not, we implement minimal, well-characterized edits and document them for regulators.

20) How are methods validated and kept in control long-term?

Method development → validation/verification (accuracy, precision, range, robustness) → version-controlled deployment. CPV includes system suitability and trend rules; method changes route through formal change control and comparability.

21) Can you separate quality sub-fractions intentionally (e.g., acidic variants)?

Yes. We design CEX/HIC fractionation with real-time pooling rules. Fractions are recombined to spec or used for mechanism studies; documentation proves clinical comparability where required.

22) How do you manage supply risk for glycan-critical raw materials?

Dual-source where possible, incoming fingerprinting (NMR/LC-MS for key excipients), and lot equivalence studies. CPV tracks any drift linked to raw-material changes.

23) Do you support controlled de-glycosylation or glycan “simplification”?

For certain analytics or MoA studies, yes—EndoS/PNGase or process-guided simplification—strictly segregated from GMP manufacturing trains, with dedicated equipment and release to prevent cross-risk.

24) What if we need accelerated timelines?

We run parallel workstreams: clone/DoE/PAT setup and early DSP in lockstep; enabling analytics validated first; perfusion/continuous capture considered if it compresses cycle time without CQA risk. Decision gates include glycan stability data.

25) What makes Elise Biopharma the safest bet for glycoengineering at scale?

Physics-anchored twins, validated PAT/MPC, clone selection under perturbation, orthogonal DSP, viscosity-aware formulation, and audit-grade documentation. Add our 120,000-ft² Massachusetts biologics facility and you get capacity, analytics, and compliance in one cohesive system.

Ready to elevate your glycoform profiles?
Partner with Elise Biopharma—a premier, audit-proven glycoengineering CDMO—where glycan quality is not a hope but a controlled output.

Email our team at info@elisebiopharma.com